ClinicalTrials.gg
CompletedNCT00373958Updated Feb 21, 2013Results posted

Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine

A Phase 3 interventional study of 13 valent pneumococcal conjugate vaccine and 7vPnc pneumococcal conjugate vaccine in Vaccines, Pneumococcal, sponsored by Pfizer. Completed at 37 sites in United States. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-02-21.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
666
Allocation
Randomized
Ages
42 Days to 98 Days
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal vaccine (13vPnC) compare to the 7-valent pneumococcal vaccine (7vPnC) and to compare the immune response to concomitant vaccines administered with 13vPnC and 7vPnC.

02

Conditions studied

  • Vaccines, Pneumococcal
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
42 Days to 98 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy 2-month-old infants.
  • Available for the entire study period.

Exclusion criteria

Exclusion criteria:

  • Previous vaccination with any vaccine before the start of the study.
  • Known to vaccination.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
666 participants (actual)

Study arms

  • Experimental
    13vPnC vaccine

    Biological: 13 valent pneumococcal conjugate vaccine

  • Active comparator
    7vPnC vaccine

    Biological: 7vPnc pneumococcal conjugate vaccine

Interventions

  • 1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.

  • Biological7vPnc pneumococcal conjugate vaccine

    1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series

    Percentages of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after the 3-dose infant series (7 months of age)

  2. Geometric Mean Antibody Concentration in 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose

    Antibody concentration/geometric mean concentration as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: 1 Month After the Toddler Dose

  3. Percentage of Participants Achieving Predefined Antibody Levels for Haemophilus Influenzae Type b, Diphtheria Toxoid, and Pertussis Antigens in 13vPnC Group Relative to 7vPnC Group After the Infant Series

    Predefined Antibody Levels for Haemophilus Influenzae Type b (\[Hib\] 0.15 µg/mL or 1.0 µg/mL), Diphtheria Toxoid (0.1 International Units \[IU\]/mL), and Pertussis antigens (Pertussis filamentous hemagglutinin \[FHA\] 40.5 Elisa Units \[EU\]/mL, Pertussis toxoid \[PT\] 16.5 EU/mL, Pertussis pertactin \[PRN\] 26 EU/mL).

    Time frame: One Month After the Infant Series (7 months of age)

  4. Percentage of Participants Reporting Pre-specified Systemic Events

    Systemic events (any fever \[Fv\] ≥ 38 degrees Celsius \[C\], decreased (decr.) appetite, irritability, increased (incr.) sleep, decreased sleep, and hives \[urticaria\], use of antipyretic medication \[med\] to treat or prevent symptoms \[sx\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 7 days after each dose

  5. Percentage of Participants Reporting Pre-specified Local Reactions

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (\[Sig.\], present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (\[Mod.\], 2.5 to 7.0 cm); Severe (\[Sev.\], \> 7.0 cm). Participants may have been represented in more than 1 category.

    Time frame: Within 7 days after each dose

Secondary outcomes

  1. Percentage of Participants Achieving Predefined Antibody Levels for Concomitant Vaccine Antigens Induced by Measles, Mumps, Rubella, Varicella (MMR-V) and Haemophilus Influenzae Type b (Hib)

    Time frame: One month after toddler dose (13 to 16 months of age)

  2. Geometric Mean Antibody Concentration of Hib PRP in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose

    Time frame: one month after the toddler dose

  3. Geometric Mean Antibody Concentration of Measles, Mumps, and Varicella ELISA in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose

    Normalization was performed for unit of measure "index value" as Index Value of 1.00 = 10 mIU/mL.

    Time frame: one month after the toddler dose

  4. Geometric Mean Antibody Concentration of Rubella in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose

    Time frame: one month after the toddler dose

  5. Percentage of Participants Achieving Functional Antibody Titer ≥1:8 as Measured by Opsonophagocytic Activity Assay (OPA) in 13vPnC Group Relative to 7vPnC Group the 3-Dose Infant Series and the Toddler Dose

    Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after infant series and one month after toddler dose

  6. Geometric Mean Titer (GMT) as Measured by Opsonophagocytic Activity Assay (OPA) in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series and the Toddler Dose

    Geometric mean titer (GMT) as measured by opsonophagocytic activity assay (OPA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: one month after the infant series and the toddler dose

07

Results

Posted Feb 21, 2013

Participant flow

Participants were recruited in the United States from September 2006 to January 2008.

Infant Series
Participant flow — Infant Series
Milestone13vPnC7vPnC
Started334332
Vaccinated dose 1332331
Vaccinated dose 2309305
Vaccinated dose 3298300
Completed294290
Not completed4042
Withdrew: Withdrawal by subject1315
Withdrew: Failed to return813
Withdrew: Lost to follow-up65
Withdrew: Protocol violation37
Withdrew: Lost kaiser coverage40
Withdrew: Child relocated10
Withdrew: Consent was not received10
Withdrew: Adverse event31
Withdrew: Physician decision11
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC7vPnC
Started294290
Withdrawn after infant series2225
Vaccinated toddler dose272265
Completed264252
Not completed3038
Withdrew: Lost to follow-up58
Withdrew: Withdrawal by subject22
Withdrew: Failed to return12
Withdrew: Protocol violation01
Withdrew: Withdrawn after infant series2225

Outcome measures

PrimaryPercentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series

Percentages of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after the 3-dose infant series (7 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series
percentage of participants13vPnC7vPnC
Common Serotypes - Serotype 4 (n=252,251)94.4 (90.9 to 96.9)98.0 (95.4 to 99.4)
Common Serotypes - Serotype 6B (n=252,250)87.3 (82.5 to 91.1)92.8 (88.9 to 95.7)
Common Serotypes - Serotype 9V (n=252,252)90.5 (86.2 to 93.8)98.4 (96.0 to 99.6)
Common Serotypes - Serotype 14 (n=251,252)97.6 (94.9 to 99.1)97.2 (94.4 to 98.9)
Common Serotypes - Serotype 18C (n=252,252)96.8 (93.8 to 98.6)98.4 (96.0 to 99.6)
Common Serotypes - Serotype 19F (n=252,251)98.0 (95.4 to 99.4)97.6 (94.9 to 99.1)
Common Serotypes - Serotype 23F (n=252,252)90.5 (86.2 to 93.8)94.0 (90.4 to 96.6)
Additional Serotypes - Serotype 1 (n=252,248)95.6 (92.3 to 97.8)1.6 (0.4 to 4.1)
Additional Serotypes - Serotype 3 (n=249,241)63.5 (57.1 to 69.4)4.6 (2.3 to 8.0)
Additional Serotypes - Serotype 5 (n=252,197)89.7 (85.2 to 93.1)31.0 (24.6 to 37.9)
Additional Serotypes - Serotype 6A (n=252,240)96.0 (92.8 to 98.1)42.5 (36.2 to 49.0)
Additional Serotypes - Serotype 7F (n=252,248)98.4 (96.0 to 99.6)2.8 (1.1 to 5.7)
Additional Serotypes - Serotype 19A (n=251,238)98.4 (96.0 to 99.6)86.6 (81.6 to 90.6)
Statistical analysis
  • 13vPnC vs 7vPnC · Difference: -3.6 · 95% CI -7.3 to -0.1
  • 13vPnC vs 7vPnC · Difference: -5.5 · 95% CI -10.9 to -0.1
  • 13vPnC vs 7vPnC · Difference: -7.9 · 95% CI -12.4 to -4.0
  • 13vPnC vs 7vPnC · Difference: 0.4 · 95% CI -2.7 to 3.5
  • 13vPnC vs 7vPnC · Difference: -1.6 · 95% CI -4.7 to 1.2
  • 13vPnC vs 7vPnC · Difference: 0.4 · 95% CI -2.4 to 3.4
  • 13vPnC vs 7vPnC · Difference: -3.6 · 95% CI -8.5 to 1.2
PrimaryGeometric Mean Antibody Concentration in 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose

Antibody concentration/geometric mean concentration as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
1 Month After the Toddler Dose
Reported as:
Geometric mean · μg/mL
Geometric Mean Antibody Concentration in 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose
μg/mL13vPnC7vPnC
Common Serotypes - Serotype 4 (n=235,223)3.73 (3.28 to 4.24)5.49 (4.91 to 6.13)
Common Serotypes - Serotype 6B (n=234,223)11.53 (9.99 to 13.30)15.63 (13.80 to 17.69)
Common Serotypes - Serotype 9V (n=234,223)2.62 (2.32 to 2.94)3.63 (3.25 to 4.05)
Common Serotypes - Serotype 14 (n=235,223)9.11 (7.95 to 10.45)12.72 (11.22 to 14.41)
Common Serotypes - Serotype 18C (n=236,223)3.20 (2.82 to 3.64)4.70 (4.18 to 5.28)
Common Serotypes - Serotype 19F (n=235,223)6.60 (5.85 to 7.44)5.60 (4.87 to 6.43)
Common Serotypes - Serotype 23F (n=234,222)5.07 (4.41 to 5.83)7.84 (6.91 to 8.90)
Additional Serotypes - Serotype 1 (n=235,223)5.06 (4.43 to 5.80)0.03 (0.03 to 0.03)
Additional Serotypes - Serotype 3 (n=232,223)0.94 (0.83 to 1.05)0.07 (0.05 to 0.08)
Additional Serotypes - Serotype 5 (n=235,223)3.72 (3.31 to 4.18)0.55 (0.47 to 0.64)
Additional Serotypes - Serotype 6A (n=235,223)8.20 (7.30 to 9.20)1.87 (1.60 to 2.19)
Additional Serotypes - Serotype 7F (n=235,223)5.67 (5.01 to 6.42)0.05 (0.04 to 0.05)
Additional Serotypes - Serotype 19A (n=236,223)8.55 (7.64 to 9.56)3.54 (3.15 to 3.98)
Statistical analysis
  • 13vPnC vs 7vPnC · Ratio: 0.68 · 95% CI 0.57 to 0.80
  • 13vPnC vs 7vPnC · Ratio: 0.74 · 95% CI 0.61 to 0.89
  • 13vPnC vs 7vPnC · Ratio: 0.72 · 95% CI 0.62 to 0.85
  • 13vPnC vs 7vPnC · Ratio: 0.72 · 95% CI 0.60 to 0.86
  • 13vPnC vs 7vPnC · Ratio: 0.68 · 95% CI 0.57 to 0.81
  • 13vPnC vs 7vPnC · Ratio: 1.18 · 95% CI 0.98 to 1.41
  • 13vPnC vs 7vPnC · Ratio: 0.65 · 95% CI 0.54 to 0.78
PrimaryPercentage of Participants Achieving Predefined Antibody Levels for Haemophilus Influenzae Type b, Diphtheria Toxoid, and Pertussis Antigens in 13vPnC Group Relative to 7vPnC Group After the Infant Series

Predefined Antibody Levels for Haemophilus Influenzae Type b (\[Hib\] 0.15 µg/mL or 1.0 µg/mL), Diphtheria Toxoid (0.1 International Units \[IU\]/mL), and Pertussis antigens (Pertussis filamentous hemagglutinin \[FHA\] 40.5 Elisa Units \[EU\]/mL, Pertussis toxoid \[PT\] 16.5 EU/mL, Pertussis pertactin \[PRN\] 26 EU/mL).

Time frame:
One Month After the Infant Series (7 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Predefined Antibody Levels for Haemophilus Influenzae Type b, Diphtheria Toxoid, and Pertussis Antigens in 13vPnC Group Relative to 7vPnC Group After the Infant Series
Percentage of participants13vPnC7vPnC
Hib 0.15 µg/mL (n=237,230)97.9 (95.1 to 99.3)97.8 (95.0 to 99.3)
Hib 1.0 µg/mL (n=237,230)77.6 (71.8 to 82.8)78.3 (72.4 to 83.4)
Diphtheria [IU]/mL (n=233,230)95.7 (92.2 to 97.9)96.1 (92.7 to 98.2)
FHA [EU]/mL (n=239,240)96.7 (93.5 to 98.5)95.0 (91.4 to 97.4)
PT [EU]/mL (n=239,240)94.1 (90.4 to 96.8)95.0 (91.4 to 97.4)
PRN [EU]/mL (n=239,240)93.7 (89.9 to 96.4)95.8 (92.5 to 98.0)
Statistical analysis
  • 13vPnC vs 7vPnC · Difference: 0.1 · 95% CI -2.9 to 3.1
  • 13vPnC vs 7vPnC · Difference: -0.6 · 95% CI -8.3 to 7.0
  • 13vPnC vs 7vPnC · Difference: -0.4 · 95% CI -4.3 to 3.5
  • 13vPnC vs 7vPnC · Difference: 1.7 · 95% CI -2.1 to 5.6
  • 13vPnC vs 7vPnC · Difference: -0.9 · 95% CI -5.2 to 3.4
  • 13vPnC vs 7vPnC · Difference: -2.1 · 95% CI -6.4 to 2.0
SecondaryPercentage of Participants Achieving Predefined Antibody Levels for Concomitant Vaccine Antigens Induced by Measles, Mumps, Rubella, Varicella (MMR-V) and Haemophilus Influenzae Type b (Hib)
Time frame:
One month after toddler dose (13 to 16 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Predefined Antibody Levels for Concomitant Vaccine Antigens Induced by Measles, Mumps, Rubella, Varicella (MMR-V) and Haemophilus Influenzae Type b (Hib)
percentage of participants13vPnC7vPnC
Measles ≥1.10 I.V. (n=221,210)96.4 (93.0 to 98.4)97.1 (93.9 to 98.9)
Mumps ≥1.10 I.V. (n=221,210)76.5 (70.3 to 81.9)72.9 (66.3 to 78.7)
Rubella ≥15 IU/mL (n=209,204)91.9 (87.3 to 95.2)90.7 (85.8 to 94.3)
Varicella ≥1.09 I.V. (n=221,210)26.7 (21.0 to 33.0)21.9 (16.5 to 28.1)
Hib (PRP) 0.15 µg/mL (n=230,214)100.0 (98.4 to 100.0)100.0 (98.3 to 100.0)
Hib (PRP) 1.0 µg/mL (n=230,214)90.4 (85.9 to 93.9)92.1 (87.6 to 95.3)
Statistical analysis
  • 13vPnC vs 7vPnC · Difference: 0.0 · 95% CI -1.6 to 1.7
  • 13vPnC vs 7vPnC · Difference: -1.6 · 95% CI -7.1 to 3.8
  • 13vPnC vs 7vPnC · Difference: -0.8 · 95% CI -4.5 to 2.9
  • 13vPnC vs 7vPnC · Difference: 3.6 · 95% CI -4.7 to 11.9
  • 13vPnC vs 7vPnC · Difference: 1.2 · 95% CI -4.4 to 6.9
  • 13vPnC vs 7vPnC · Difference: 4.8 · 95% CI -3.4 to 13.0
SecondaryGeometric Mean Antibody Concentration of Hib PRP in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
Time frame:
one month after the toddler dose
Reported as:
Geometric mean · µg/mL
Geometric Mean Antibody Concentration of Hib PRP in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
µg/mL13vPnC7vPnC
Geometric Mean Antibody Concentration of Hib PRP in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose6.84 (5.85 to 7.99)7.30 (6.21 to 8.59)
Statistical analysis
  • 13vPnC vs 7vPnC · Ratio: 0.94 · 95% CI 0.75 to 1.17
SecondaryGeometric Mean Antibody Concentration of Measles, Mumps, and Varicella ELISA in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose

Normalization was performed for unit of measure "index value" as Index Value of 1.00 = 10 mIU/mL.

Time frame:
one month after the toddler dose
Reported as:
Geometric mean · index value
Geometric Mean Antibody Concentration of Measles, Mumps, and Varicella ELISA in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
index value13vPnC7vPnC
Measles1.98 (1.81 to 2.16)2.06 (1.90 to 2.23)
Mumps1.32 (1.19 to 1.46)1.32 (1.20 to 1.45)
Varicella0.74 (0.69 to 0.79)0.73 (0.69 to 0.77)
Statistical analysis
  • 13vPnC vs 7vPnC · Ratio: 0.96 · 95% CI 0.85 to 1.08
  • 13vPnC vs 7vPnC · Ratio: 1.00 · 95% CI 0.87 to 1.14
  • 13vPnC vs 7vPnC · Ratio: 1.01 · 95% CI 0.92 to 1.10
SecondaryGeometric Mean Antibody Concentration of Rubella in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
Time frame:
one month after the toddler dose
Reported as:
Geometric mean · IU/mL
Geometric Mean Antibody Concentration of Rubella in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
IU/mL13vPnC7vPnC
Geometric Mean Antibody Concentration of Rubella in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose76.53 (64.55 to 90.72)97.69 (82.28 to 115.98)
Statistical analysis
  • 13vPnC vs 7vPnC · Ratio: 0.78 · 95% CI 0.62 to 1.00
PrimaryPercentage of Participants Reporting Pre-specified Systemic Events

Systemic events (any fever \[Fv\] ≥ 38 degrees Celsius \[C\], decreased (decr.) appetite, irritability, increased (incr.) sleep, decreased sleep, and hives \[urticaria\], use of antipyretic medication \[med\] to treat or prevent symptoms \[sx\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 7 days after each dose
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events
Percentage of participants13vPnC Dose 17vPnC Dose 113vPnC Dose 27vPnC Dose 213vPnC Dose 37vPnC Dose 313vPnC Toddler Dose7vPnC Toddler Dose
Fv≥38°C but ≤39°C(n=196,203,146,151,123,106,99,7624.021.243.240.439.837.753.551.3
Fv>39°C but ≤40°C(n=177,187,118,123,94,81,61,48)2.80.02.54.98.52.56.612.5
Fv >40°C (n=174,187,116,121,87,80,60,45)0.00.00.00.80.01.31.70.0
Decr. appetite (n=228,238,177,174,147,136,116,110)54.845.459.952.359.259.665.573.6
Irritability (n=289,290,236,236,216,218,199,175)89.685.989.891.588.492.292.093.1
Incr. sleep (n=268,270,203,200,164,149,115,109)79.578.579.373.571.369.870.474.3
Decr. sleep (n=221,236,169,172,154,134,113,95)45.747.949.155.860.463.458.464.2
Hives (urticaria) (n=178,188,118,120,89,79,62,47)1.71.12.50.04.50.04.86.4
Med-treat sx (n=257,266,221,221,203,187,162,138)78.671.882.481.982.385.684.087.7
Med-prevent sx (n=272,274,233,231,202,189,164,162)75.074.886.783.581.284.188.490.7
PrimaryPercentage of Participants Reporting Pre-specified Local Reactions

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (\[Sig.\], present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (\[Mod.\], 2.5 to 7.0 cm); Severe (\[Sev.\], \> 7.0 cm). Participants may have been represented in more than 1 category.

Time frame:
Within 7 days after each dose
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions
Percentage of participants13vPnC Dose 17vPnC Dose 113vPnC Dose 27vPnC Dose 213vPnC Dose 37vPnC Dose 313vPnC Toddler Dose7vPnC Toddler Series
Tenderness-Any (n=264,270,200,216,178,173,149,147)72.772.277.075.978.780.981.284.4
Tenderness-Sig. (n=182,195,123,131,91,86,65,49)13.79.210.611.58.89.315.412.2
Swelling-Any (n=201,216,141,146,116,103,91,73)27.423.631.229.537.936.944.050.7
Swelling-Mild (n=199,212,141,142,113,103,90,71)23.121.229.826.135.436.943.346.5
Swelling-Mod. (n=176,193,118,126,91,82,68,49)6.85.25.17.16.66.114.714.3
Swelling-Sev. (n=172,187,116,120,87,79,59,44)0.00.00.00.00.00.00.00.0
Redness-Any (n=202,223,155,164,131,118,103,87)35.632.345.237.848.950.054.465.5
Redness-Mild (n=200,220,155,162,128,117,102,85)34.531.444.537.047.748.753.963.5
Redness-Mod. (n=177,191,117,124,91,80,62,50)4.52.61.73.25.55.08.114.0
Redness-Sev. (n=173,186,116,120,87,79,59,44)0.00.00.00.00.00.00.00.0
SecondaryPercentage of Participants Achieving Functional Antibody Titer ≥1:8 as Measured by Opsonophagocytic Activity Assay (OPA) in 13vPnC Group Relative to 7vPnC Group the 3-Dose Infant Series and the Toddler Dose

Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after infant series and one month after toddler dose
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Functional Antibody Titer ≥1:8 as Measured by Opsonophagocytic Activity Assay (OPA) in 13vPnC Group Relative to 7vPnC Group the 3-Dose Infant Series and the Toddler Dose
percentage of participants13vPnC After Infant Series7vPnC After Infant Series13vPnC After Toddler Dose7vPnC After Toddler Dose
Common Serotypes - Serotype 4 (n=92,92,88,92)97.8 (92.4 to 99.7)98.9 (94.1 to 100.0)98.9 (93.8 to 100.0)98.9 (94.1 to 100.0)
Common Serotypes - Serotype 6B (n=94,94,92,95)98.9 (94.2 to 100.0)100.0 (96.2 to 100.0)98.9 (94.1 to 100.0)100.0 (96.2 to 100.0)
Common Serotypes - Serotype 9V (n=93,94,90,94)100.0 (96.1 to 100.0)98.9 (94.2 to 100.0)98.9 (94.0 to 100.0)100.0 (96.2 to 100.0)
Common Serotypes - Serotype 14 (n=94,94,92,96)100.0 (96.2 to 100.0)100.0 (96.2 to 100.0)100.0 (96.1 to 100.0)100.0 (96.2 to 100.0)
Common Serotypes - Serotype 18C (n=94,94,91,96)100.0 (96.2 to 100.0)100.0 (96.2 to 100.0)98.9 (94.0 to 100.0)100.0 (96.2 to 100.0)
Common Serotypes - Serotype 19F (n=94,94,92,96)90.4 (82.6 to 95.5)92.6 (85.3 to 97.0)96.7 (90.8 to 99.3)94.8 (88.3 to 98.3)
Common Serotypes - Serotype 23F (n=94,94,90,92)98.9 (94.2 to 100.0)98.9 (94.2 to 100.0)98.9 (94.0 to 100.0)100.0 (96.1 to 100.0)
Additional Serotypes - Serotype 1 (n=92,92,89,92)98.9 (94.1 to 100.0)9.8 (4.6 to 17.8)98.9 (93.9 to 100.0)12.0 (6.1 to 20.4)
Additional Serotypes - Serotype 3 (n=94,94,91,96)96.8 (91.0 to 99.3)21.3 (13.5 to 30.9)97.8 (92.3 to 99.7)43.8 (33.6 to 54.3)
Additional Serotypes - Serotype 5 (n=91,93,91,96)92.3 (84.8 to 96.9)2.2 (0.3 to 7.6)98.9 (94.0 to 100.0)5.2 (1.7 to 11.7)
Additional Serotypes - Serotype 6A (n=94,94,92,96)100.0 (96.2 to 100.0)77.7 (67.9 to 85.6)98.9 (94.1 to 100.0)94.8 (88.3 to 98.3)
Additional Serotypes - Serotype 7F (n=94,89,91,92)100.0 (96.2 to 100.0)76.4 (66.2 to 84.8)100.0 (96.0 to 100.0)80.4 (70.9 to 88.0)
Additional Serotypes-Serotype 19A (n=93,92,91,94)91.4 (83.8 to 96.2)16.3 (9.4 to 25.5)97.8 (92.3 to 99.7)53.2 (42.6 to 63.6)
SecondaryGeometric Mean Titer (GMT) as Measured by Opsonophagocytic Activity Assay (OPA) in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series and the Toddler Dose

Geometric mean titer (GMT) as measured by opsonophagocytic activity assay (OPA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
one month after the infant series and the toddler dose
Reported as:
Geometric mean · titer
Geometric Mean Titer (GMT) as Measured by Opsonophagocytic Activity Assay (OPA) in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series and the Toddler Dose
titer13vPnC After the Infant Series7vPnC After the Infant Series13vPnC After the Toddler Dose7vPnC After the Toddler Dose
Common Serotypes -Serotype 4 (n=92,92,88,92)359.32 (276.04 to 467.72)535.68 (421.13 to 681.37)1179.98 (847.34 to 1643.20)1492.46 (1114.40 to 1998.78)
Common Serotypes - Serotype 6B (n=94,94,92,95)1054.65 (817.34 to 1360.87)1513.66 (1206.64 to 1898.81)3099.51 (2337.02 to 4110.79)4066.22 (3243.42 to 5097.76)
Common Serotypes - Serotype 9V (n=93,94,90,94)4035.40 (2932.68 to 5552.75)3259.01 (2288.43 to 4641.25)11856.03 (8809.85 to 15955.49)18032.33 (14124.99 to 23020.53)
Common Serotypes - Serotype 14 (n=94,94,92,96)1240.41 (934.93 to 1645.69)1480.55 (1133.40 to 1934.02)2002.23 (1452.54 to 2759.93)2365.87 (1870.56 to 2992.34)
Common Serotypes - Serotype 18C (n=94,94,91,96)275.59 (210.33 to 361.10)375.64 (291.68 to 483.75)993.27 (754.08 to 1308.33)1722.16 (1326.59 to 2235.67)
Common Serotypes - Serotype 19F (n=94,94,92,96)54.42 (40.20 to 73.65)44.92 (33.90 to 59.52)199.65 (144.22 to 276.38)167.20 (121.35 to 230.37)
Common Serotypes - Serotype 23F (n=94,94,90,92)791.07 (604.96 to 1034.44)923.56 (708.59 to 1203.74)2723.25 (1960.67 to 3782.41)4981.68 (3885.71 to 6386.76)
Additional Serotypes - Serotype 1 (n=92,92,89,92)51.83 (38.84 to 69.16)4.41 (4.06 to 4.80)164.23 (113.83 to 236.93)5.01 (4.22 to 5.96)
Additional Serotypes - Serotype 3 (n=94,94,91,96)120.67 (92.38 to 157.62)6.70 (5.27 to 8.52)380.41 (300.19 to 482.08)11.81 (8.68 to 16.08)
Additional Serotypes - Serotype 5 (n=91,93,91,96)90.86 (67.10 to 123.02)4.15 (3.94 to 4.38)300.41 (229.39 to 393.40)4.69 (3.99 to 5.51)
Additional Serotypes - Serotype 6A (n=94,94,92,96)979.68 (783.04 to 1225.71)100.35 (66.22 to 152.08)2241.79 (1706.71 to 2944.63)538.54 (374.83 to 773.75)
Additional Serotypes - Serotype 7F (n=94,89,91,92)9493.77 (7339.13 to 12280.98)128.00 (79.55 to 205.97)11629.44 (9053.62 to 14938.11)267.84 (164.49 to 436.11)
Additional Serotypes-Serotype 19A (n=93,92,91,94)151.94 (105.16 to 219.52)6.53 (5.01 to 8.50)1024.00 (774.12 to 1354.54)28.65 (18.58 to 44.17)

Adverse events

Collected over Adverse events were collected throughout the study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC Infant Series—17/332 (5.1%)272/332 (81.9%)
7vPnC Infant Series—16/331 (4.8%)263/331 (79.5%)
13vPnC Post Infant Series—5/332 (1.5%)31/332 (9.3%)
7vPnC Post Infant Series—7/330 (2.1%)29/330 (8.8%)
13vPnC Toddler Series—3/267 (1.1%)183/267 (68.5%)
7vPnC Toddler Series—4/258 (1.6%)163/258 (63.2%)
13vPnC 6-Month Follow-up—9/330 (2.7%)11/330 (3.3%)
7vPnC 6-Month Follow-up—5/329 (1.5%)10/329 (3%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
Event13vPnC Infant Series7vPnC Infant Series13vPnC Post Infant Series7vPnC Post Infant Series13vPnC Toddler Series7vPnC Toddler Series13vPnC 6-Month Follow-up7vPnC 6-Month Follow-up
BronchiolitisInfections and infestations4/3326/3310/3322/3300/2670/2581/3300/329
Respiratory syncytial virus bronchiolitisInfections and infestations3/3322/3310/3320/3300/2670/2581/3301/329
Status asthmaticusRespiratory, thoracic and mediastinal disorders0/3320/3311/3322/3301/2670/2580/3301/329
Respiratory syncytial virus infectionInfections and infestations0/3322/3310/3320/3300/2670/2581/3300/329
PyrexiaGeneral disorders2/3320/3310/3320/3300/2670/2580/3300/329
AsthmaRespiratory, thoracic and mediastinal disorders0/3320/3310/3320/3300/2671/2581/3301/329
CoughRespiratory, thoracic and mediastinal disorders1/3321/3310/3320/3300/2671/2580/3300/329
DehydrationMetabolism and nutrition disorders0/3320/3310/3320/3300/2671/2580/3300/329
Febrile convulsionNervous system disorders1/3320/3311/3320/3300/2671/2580/3300/329
GastroenteritisInfections and infestations0/3320/3310/3320/3300/2671/2580/3300/329
Most frequent other events
Showing 10 of 321
Most frequent other events
Event13vPnC Infant Series7vPnC Infant Series13vPnC Post Infant Series7vPnC Post Infant Series13vPnC Toddler Series7vPnC Toddler Series13vPnC 6-Month Follow-up7vPnC 6-Month Follow-up
IrritabilityGeneral disorders259/289249/290——183/199163/175——
IrritabilityGeneral disorders191/216201/218——————
IrritabilityGeneral disorders212/236216/236——————
Tenderness (Any)Skin and subcutaneous tissue disorders192/264195/270——121/149124/147——
Tenderness (Any)Skin and subcutaneous tissue disorders140/178140/173——————
Increased sleepGeneral disorders213/268212/270——81/11581/109——
Increased sleepGeneral disorders161/203147/200——————
Tenderness (Any)Skin and subcutaneous tissue disorders154/200164/216——————
Decreased appetiteGeneral disorders125/228108/238——76/11681/110——
Increased sleepGeneral disorders117/164104/149——————

Baseline characteristics

Age Continuous
Age Continuous(months)13vPnC7vPnCTotal
Mean2.1 ± 0.32.1 ± 0.32.1 ± 0.3
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC7vPnCTotal
Female165139304
Male169193362
08

Study locations

37 sites
  • Fayetteville, Arkansas 72703, United States
  • Jonesboro, Arkansas 72401, United States
  • Little Rock, Arkansas 72205, United States
  • Downey, California 90242, United States
  • Fontana, California 92335, United States
  • Loma Linda, California 92354, United States
  • Paramount, California 90723, United States
  • Riverside, California 92505, United States
  • Centennial, Colorado 80112, United States
  • Norwich, Connecticut 06360, United States
  • Tampa, Florida 33606, United States
  • Marietta, Georgia 30062, United States
  • Woodstock, Georgia 30189, United States
  • Chicago, Illinois 60612, United States
  • Park Ridge, Illinois 60068, United States
  • Overland Park, Kansas 66212, United States
  • Bardstown, Kentucky 40004, United States
  • Louisville, Kentucky 40202, United States
  • Louisville, Kentucky 40207, United States
  • Bronx, New York 10467, United States
  • Rochester, New York 14620, United States
  • Cincinnati, Ohio 45245, United States
  • Cleveland, Ohio 44118, United States
  • Mason, Ohio 45040, United States
  • Latrobe, Pennsylvania 15650, United States
  • Pittsburgh, Pennsylvania 15227, United States
  • Pittsburgh, Pennsylvania 15236, United States
  • Pittsburg, Pennsylvania 15241, United States
  • Sellersville, Pennsylvania 18960, United States
  • Wexford, Pennsylvania 15090, United States
  • Charleston, South Carolina 29425, United States
  • Jackson, Tennessee 38305, United States
  • The Woodlands, Texas 77380, United States
  • Murray, Utah 84107, United States
  • Provo, Utah 84604, United States
  • Richmond, Virginia 23219, United States
  • Vienna, Virginia 22180, United States
09

References and documents

Publications

  • Bryant KA, Gurtman A, Girgenti D, Reisinger K, Johnson A, Pride MW, Patterson S, Devlin C, Gruber WC, Emini EA, Scott DA. Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013 Apr;32(4):383-8. doi: 10.1097/INF.0b013e318279e9a9. PubMed 23104129 ↗
  • Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, Jansen KU, Love J, Gruber WC, Emini EA, Scott DA; 004 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010 Sep;126(3):e493-505. doi: 10.1542/peds.2009-3027. Epub 2010 Aug 23. PubMed 20732948 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2013, 4 years 8 months after primary completion. A results delay was requested in Feb 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2006
First posted
Sep 8, 2006
Start
Sep 2006
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results delay requested
Feb 26, 2009
Results first posted
Feb 21, 2013
Last update
Feb 21, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00373958
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 8, 2006
Start date
Sep 2006
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Feb 21, 2013
Last update
Feb 21, 2013

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion